Recent share performance and business snapshot

CareDx (CDNA) has drawn investor attention after recent share price moves, with the stock last closing at $21.63 and recording mixed short term returns over the past week, month and past 3 months.

The company focuses on transplant related diagnostics and software, with US$412.82 million in annual revenue and a reported net income loss of US$8.192 million, placing it among mid cap US healthcare stocks.

Recent share price momentum looks constructive, with a 7 day share price return of 5.05% and a 90 day share price return of 12.36%. The 1 year total shareholder return of 27.61% contrasts with a 5 year total shareholder return that is down 73.10%.

If CareDx has you looking closer at healthcare diagnostics and organ health, it can be worth scanning the broader opportunity set through 34 healthcare AI stocks

With CareDx posting positive recent returns, trading below the average analyst price target and reporting a relatively small loss on more than US$400 million of revenue, should you see value here, or assume the market is already pricing in future growth?

Most Popular Narrative: 13% Undervalued

The most followed valuation narrative for CareDx pegs fair value at $24.80 per share, a step above the last close of $21.63. On that view, the stock is framed as modestly undervalued.

Significant progress in payer coverage including millions of new covered lives, expanded in-network status, and the implementation of a unique CPT code for AlloSure indicates a catalyst for sustained increases in ASP (average selling price) and recurring revenue streams, which can directly enhance future profitability and margin expansion.

Curious what sort of revenue growth, margin lift and future earnings multiple are baked into that fair value line? The core assumptions describe a much more ambitious earnings profile than current results, and the entire calculation depends on a handful of tightly linked projections.

Result: Fair Value of $24.80 (UNDERVALUED)

However, this hinges on reimbursement and policy outcomes, as bundled payments or tighter Medicare coverage could potentially dent AlloSure and HeartCare volumes and compress margins.

Next Steps

With the mixed signals in this story, it helps to look past headlines and run through the numbers yourself before forming a view. To see what investors currently see as the main positives, check out the 3 key rewards.

Looking for more investment ideas?

If CareDx has sharpened your focus, do not stop here. Casting a wider net across quality stock ideas can help you build a more resilient portfolio.

• Target potential bargains by scanning companies that screen as high quality yet priced attractively through the 48 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks that qualify as 10 dividend fortresses.
• Prioritise stability and sleep better at night by checking companies highlighted in the 69 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.